P478 Platelet-related indicators for predicting vedolizumab response in patients with Ulcerative Colitis

Abstract Background Ulcerative Colitis (UC) combine both inflammation and coagulation in their pathogenesis clinical manifestations. Although platelets (PLT) are well known for role hemostasis, there a rising number of studies supporting considerable as inflammatory amplifiers chronic conditions. However, whether PLT related to the efficacy biologic agents is unknown. This study aimed investigate platelet ratio before after induction therapy can be predictive biomarkers therapeutic outcomes vedolizumab UC. Methods Patients with moderate-to-severe UC receiving our hospital between November 2020 2022 were retrospectively evaluated. concomitant corticosteroid treatment≥20 mg, immunomodulators, or other conditions that could modify count excluded. The primary endpoint was response at end period (at 14 weeks). We analyzed association count, neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-to-lymphocyte (MLR), C-reactive protein (CRP), fecal calprotectin, vedolizumab. above indicators nonresponse groups compared via univariate analysis. independent risk factors identified multivariate Results Seventy-one patients active started treatment 20 (28.2%) experienced loss (LOR) therapy. albumin, CRP, NLR, PLR, MLR, Particul Mayo score LOR significantly differed. Platelet cut-off value 1.077 LOR, using receiver operating characteristic analysis (sensitivity:78.0%, specificity:81.8%). A revealed significant relationship (P＜0.05). Multivariate indicated an prognostic factor (OR=11.219, 95% CI:3.316-37.959, P＜0.05). Conclusion useful marker treated vedolizumab, may contribute appropriate use LOR. large sample from multiple centers needed validate platelet-related measures rate response.